Adaptive drug trial for newly diagnosed breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests personalized, changing treatment plans (given before surgery) to find better options for your specific breast tumor. You may be asked for extra breast-tissue testing to help match you with the most suitable study drug(s).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have confirmed invasive breast cancer based on biopsy results.
- Your breast tumor must be large enough to measure (at least 2.5 cm) after biopsy.
- You should not have had chemotherapy for this breast cancer, and you should not have had radiation to the same breast for this cancer before starting the study.
- You must be 18 or older, able to do study activities (performance status 0–1), and willing to sign consent forms.
- You need to have a safe tumor and body health baseline: no distant spread on standard scans, good blood counts, and good liver/kidney tests.
- You must be able to have a core biopsy again for baseline tumor testing, and you must be able to have MRI if required (no MRI-incompatible metal implants).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests different treatments tailored to your cancer's biology. It aims to find which therapy might work best for you, potentially improving outcomes. You'd receive one of the study drugs, with close monitoring and support.
This Phase 2 study tests a “precision platform” approach—treatment before surgery—based on specific test results from your breast tumor. It may help determine whether the treatment plan works better for people with particular breast cancer subtypes and healthy organ function.
This trial tests different combinations of targeted therapy and chemotherapy before surgery for HER2-positive breast cancer. It uses a special PET scan to see how well the treatment is working and to help choose the best treatment plan for each person.
This trial compares two combination treatment plans given before breast surgery (neoadjuvant therapy) for ER-positive and HER2-positive stage II–III breast cancer. It aims to see which plan works better to shrink the tumor and improve outcomes.
This study tests a personalized treatment approach for HER2-positive breast cancer. It uses regular monitoring of your tumor to adjust the treatment before surgery, aiming to improve results. It might help you by tailoring therapy to your cancer's response.
This Phase 2 study looks at how well early breast cancer shrinks with treatment and how that matches with what doctors find after surgery under the microscope. The goal is to learn better ways to predict and assess treatment success.
Hear when a new Breast Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.